FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189034905> ?p ?o ?g. }

• W3189034905 endingPage "6353" @default.
• W3189034905 startingPage "6344" @default.
• W3189034905 abstract "The programmed death 1 and ligand (PD-1/PD-L1) inhibitors have significantly altered therapeutic perspectives on non-small-cell lung cancer (NSCLC). However, their efficacy and safety are unknown since direct clinical trials have not yet been performed on them. It is also necessary to determine the economics of PD-1/PD-L1 inhibitors due to their high cost. The aim was to evaluate the efficacy, safety, and cost-effectiveness of PD-1/PD-L1 inhibitor monotherapy for advanced NSCLC patients in China with high PD-L1 expression as first-line treatment.From the PubMed, Cochrane, and Web of Science databases, we retrieved survival, progression, and safety data on PD-1/PD-L1 inhibitor monotherapy for advanced NSCLC patients. A network meta-analysis (NMA) was performed to consider PD-1/PD-L1 inhibitors in efficacy and safety. A Markov model with a full-lifetime horizon was adopted. Clinical and utility data were collected through the trial. The cost per quality-adjusted life year (QALY) was as incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed.This study included five phase III clinical trials using four drugs: nivolumab, pembrolizumab, atezolizumab, and durvalumab. The NMA demonstrated that the four drugs had similar efficacy and safety, while pembrolizumab and atezolizumab were better for than for nivolumab (hazard ratio (HR) = 0.66, 95% confidence intervals (CIs): 0.46-0.95 and HR = 0.59, 95%CI: 0.37-0.94) in progression-free survival (PFS), and the risk of a severe adverse event was higher for atezolizumab than for nivolumab and pembrolizumab. Compared with nivolumab, durvalumab, pembrolizumab, and atezolizumab had QALY of 0.19, 0.38, and 0.53, respectively, which induced ICERs of $ 197,028.8/QALY, $ 111,859.0/QALY, and $ 76,182.3/QALY, respectively.The efficacy and safety are similar among types of PD-1/PD-L1-inhibitor monotherapy. The cost-effectiveness of nivolumab appears optimal, but the other PD-1/PD-L1 inhibitors are not as cost-effective for the first-line treatment of advanced NSCLC in China." @default.
• W3189034905 created "2021-08-16" @default.
• W3189034905 creator A5003642180 @default.
• W3189034905 creator A5007421199 @default.
• W3189034905 creator A5025204831 @default.
• W3189034905 creator A5031230403 @default.
• W3189034905 creator A5047170684 @default.
• W3189034905 creator A5050056901 @default.
• W3189034905 creator A5072820962 @default.
• W3189034905 creator A5075134934 @default.
• W3189034905 date "2021-08-12" @default.
• W3189034905 modified "2023-10-17" @default.
• W3189034905 title "Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China" @default.
• W3189034905 cites W1982488143 @default.
• W3189034905 cites W1996652550 @default.
• W3189034905 cites W2002716449 @default.
• W3189034905 cites W2005295931 @default.
• W3189034905 cites W2137210918 @default.
• W3189034905 cites W2296800272 @default.
• W3189034905 cites W2527905628 @default.
• W3189034905 cites W2560367415 @default.
• W3189034905 cites W2563204578 @default.
• W3189034905 cites W2572174216 @default.
• W3189034905 cites W2635951006 @default.
• W3189034905 cites W2751792491 @default.
• W3189034905 cites W2777867648 @default.
• W3189034905 cites W2785478765 @default.
• W3189034905 cites W2785808209 @default.
• W3189034905 cites W2796582438 @default.
• W3189034905 cites W2923986778 @default.
• W3189034905 cites W2925446385 @default.
• W3189034905 cites W2948776902 @default.
• W3189034905 cites W2957427793 @default.
• W3189034905 cites W2964563066 @default.
• W3189034905 cites W2971236352 @default.
• W3189034905 cites W2973507641 @default.
• W3189034905 cites W2977511836 @default.
• W3189034905 cites W2979692290 @default.
• W3189034905 cites W2980598473 @default.
• W3189034905 cites W2995846969 @default.
• W3189034905 cites W2996681083 @default.
• W3189034905 cites W3016210953 @default.
• W3189034905 cites W3029013041 @default.
• W3189034905 cites W3029846245 @default.
• W3189034905 cites W3033517289 @default.
• W3189034905 cites W3081464123 @default.
• W3189034905 cites W3081615089 @default.
• W3189034905 cites W3084064036 @default.
• W3189034905 cites W3091399767 @default.
• W3189034905 cites W3189034905 @default.
• W3189034905 doi "https://doi.org/10.1002/cam4.4191" @default.
• W3189034905 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8446572" @default.
• W3189034905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34382361" @default.
• W3189034905 hasPublicationYear "2021" @default.
• W3189034905 type Work @default.
• W3189034905 sameAs 3189034905 @default.
• W3189034905 citedByCount "6" @default.
• W3189034905 countsByYear W31890349052021 @default.
• W3189034905 countsByYear W31890349052022 @default.
• W3189034905 countsByYear W31890349052023 @default.
• W3189034905 crossrefType "journal-article" @default.
• W3189034905 hasAuthorship W3189034905A5003642180 @default.
• W3189034905 hasAuthorship W3189034905A5007421199 @default.
• W3189034905 hasAuthorship W3189034905A5025204831 @default.
• W3189034905 hasAuthorship W3189034905A5031230403 @default.
• W3189034905 hasAuthorship W3189034905A5047170684 @default.
• W3189034905 hasAuthorship W3189034905A5050056901 @default.
• W3189034905 hasAuthorship W3189034905A5072820962 @default.
• W3189034905 hasAuthorship W3189034905A5075134934 @default.
• W3189034905 hasBestOaLocation W31890349051 @default.
• W3189034905 hasConcept C121608353 @default.
• W3189034905 hasConcept C126322002 @default.
• W3189034905 hasConcept C143998085 @default.
• W3189034905 hasConcept C197934379 @default.
• W3189034905 hasConcept C207103383 @default.
• W3189034905 hasConcept C2775949291 @default.
• W3189034905 hasConcept C2776256026 @default.
• W3189034905 hasConcept C2777701055 @default.
• W3189034905 hasConcept C2777742743 @default.
• W3189034905 hasConcept C2780030458 @default.
• W3189034905 hasConcept C2780057760 @default.
• W3189034905 hasConcept C2781053074 @default.
• W3189034905 hasConcept C44249647 @default.
• W3189034905 hasConcept C535046627 @default.
• W3189034905 hasConcept C71924100 @default.
• W3189034905 hasConceptScore W3189034905C121608353 @default.
• W3189034905 hasConceptScore W3189034905C126322002 @default.
• W3189034905 hasConceptScore W3189034905C143998085 @default.
• W3189034905 hasConceptScore W3189034905C197934379 @default.
• W3189034905 hasConceptScore W3189034905C207103383 @default.
• W3189034905 hasConceptScore W3189034905C2775949291 @default.
• W3189034905 hasConceptScore W3189034905C2776256026 @default.
• W3189034905 hasConceptScore W3189034905C2777701055 @default.
• W3189034905 hasConceptScore W3189034905C2777742743 @default.
• W3189034905 hasConceptScore W3189034905C2780030458 @default.
• W3189034905 hasConceptScore W3189034905C2780057760 @default.
• W3189034905 hasConceptScore W3189034905C2781053074 @default.
• W3189034905 hasConceptScore W3189034905C44249647 @default.

• next